Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

GAINESVILLE, Fla., January 20, 2026--neuropacs™ Corp., a leading innovator in AI-driven neurological diagnostics, announced today the successful raise of over $1.0 million in early-stage capital.

Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...

Many people's worst nightmare is being diagnosed with a terminal illness. It happens when you least expect it, and suddenly, ...

Arguably, the most important thing you can have in this life is your health. No matter how much money you have or resources ...

Cold Spring Harbor Laboratory researchers have reported that a bespoke antisense oligonucleotide can disrupt alternative ...

Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data ...

Discover expert dog health guides covering nutrition, exercise, common conditions, preventive care, and mental wellness.

NouvNeu004: Recently received I-III all-stage IND approval from the NMPA, making it the world's first cell therapy product for Multiple System Atrophy (MSA) and iRegene's third self-developed product ...